|
1
|
Stewart BW and Wild C: International
Agency for Research on Cancer. World Health Organization (ed) Lyon,
France: International Agency for Research on Cancer; pp.
6302014
|
|
2
|
Bataille V, Winnett A, Sasieni P, Bishop
Newton JA and Cuzick J: Exposure to the sun and sunbeds and the
risk of cutaneous melanoma in the UK: A case-control study. Eur J
Cancer. 40:429–435. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Balch CM, Gershenwald JE, Soong SJ,
Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG,
Ding S, et al: Final version of 2009 AJCC melanoma staging and
classification. J Clin Oncol. 27:6199–6206. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gray-Schopfer V, Wellbrock C and Marais R:
Melanoma biology and new targeted therapy. Nature. 445:851–857.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
La Porta CA: Drug resistance in melanoma:
New perspectives. Curr Med Chem. 14:387–391. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Todd JR, Scurr LL, Becker TM, Kefford RF
and Rizos H: The MAPK pathway functions as a redundant survival
signal that reinforces the PI3K cascade in c-Kit mutant melanoma.
Oncogene. 33:236–245. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Greaves WO, Verma S, Patel KP, Davies MA,
Barkoh BA, Galbincea JM, Yao H, Lazar AJ, Aldape KD, Medeiros LJ,
et al: Frequency and spectrum of BRAF mutations in a
retrospective, single-institution study of 1112 cases of melanoma.
J Mol Diagn. 15:220–226. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Flaherty KT, Infante JR, Daud A, Gonzalez
R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N,
et al: Combined BRAF and MEK inhibition in melanoma with BRAF V600
mutations. N Engl J Med. 367:1694–1703. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Davies H, Bignell GR, Cox C, Stephens P,
Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W,
et al: Mutations of the BRAF gene in human cancer. Nature.
417:949–954. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Viola JR, Rafael DF, Wagner E, Besch R and
Ogris M: Gene therapy for advanced melanoma: Selective targeting
and therapeutic nucleic acids. J Drug Deliv. 2013:897348. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Su F, Viros A, Milagre C, Trunzer K,
Bollag G, Spleiss O, Reis-Filho JS, Kong X, Koya RC, Flaherty KT,
et al: RAS mutations in cutaneous squamous-cell carcinomas
in patients treated with BRAF inhibitors. N Engl J Med.
366:207–215. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Oberholzer PA, Kee D, Dziunycz P, Sucker
A, Kamsukom N, Jones R, Roden C, Chalk CJ, Ardlie K, Palescandolo
E, et al: RAS mutations are associated with the development
of cutaneous squamous cell tumors in patients treated with RAF
inhibitors. J Clin Oncol. 30:316–321. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Baccarini M: An old kinase on a new path:
Raf and apoptosis. Cell Death Differ. 9:783–785. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Antony R, Emery CM, Sawyer AM and Garraway
LA: C-RAF mutations confer resistance to RAF inhibitors. Cancer
Res. 73:4840–4851. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Avruch J, Khokhlatchev A, Kyriakis JM, Luo
Z, Tzivion G, Vavvas D and Zhang XF: Ras activation of the Raf
kinase: Tyrosine kinase recruitment of the MAP kinase cascade.
Recent Prog Horm Res. 56:127–155. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hüser M, Luckett J, Chiloeches A, Mercer
K, Iwobi M, Giblett S, Sun XM, Brown J, Marais R and Pritchard C:
MEK kinase activity is not necessary for Raf-1 function. EMBO J.
20:1940–1951. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Avruch J, Zhou D, Fitamant J, Bardeesy N,
Mou F and Barrufet LR: Protein kinases of the Hippo pathway:
Regulation and substrates. Semin Cell Dev Biol. 23:770–784. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
ONeill E, Rushworth L, Baccarini M and
Kolch W: Role of the kinase MST2 in suppression of apoptosis by the
proto-oncogene product Raf-1. Science. 306:2267–2270. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Thomas NE, Edmiston SN, Alexander A,
Millikan RC, Groben PA, Hao H, Tolbert D, Berwick M, Busam K, Begg
CB, et al: Number of nevi and early-life ambient UV exposure are
associated with BRAF-mutant melanoma. Cancer Epidemiol
Biomarkers Prev. 16:991–997. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Praskova M, Xia F and Avruch J:
MOBKL1A/MOBKL1B phosphorylation by MST1 and MST2 inhibits cell
proliferation. Curr Biol. 18:311–321. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Harvey KF, Zhang X and Thomas DM: The
Hippo pathway and human cancer. Nat Rev Cancer. 13:246–257. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pollock PM, Harper UL, Hansen KS, Yudt LM,
Stark M, Robbins CM, Moses TY, Hostetter G, Wagner U, Kakareka J,
et al: High frequency of BRAF mutations in nevi. Nat Genet.
33:19–20. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nallet-Staub F, Marsaud V, Li L, Gilbert
C, Dodier S, Bataille V, Sudol M, Herlyn M and Mauviel A:
Pro-invasive activity of the Hippo pathway effectors YAP and TAZ in
cutaneous melanoma. J Invest Dermatol. 134:123–132. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lin L and Bivona TG: The Hippo effector
YAP regulates the response of cancer cells to MAPK pathway
inhibitors. Mol Cell Oncol. 3:e10214412015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zheng HX, Wu LN, Xiao H, Du Q and Liang
JF: Inhibitory effects of dobutamine on human gastric
adenocarcinoma. World J Gastroenterol. 20:17092–17099. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chin L, Garraway LA and Fisher DE:
Malignant melanoma: Genetics and therapeutics in the genomic era.
Genes Dev. 20:2149–2182. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hüser M, Luckett J, Chiloeches A, Mercer
K, Iwobi M, Giblett S, Sun XM, Brown J, Marais R and Pritchard C:
MEK kinase activity is not necessary for Raf-1 function. EMBO J.
20:1940–1951. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kyriakis JM: The integration of signaling
by multiprotein complexes containing Raf kinases. Biochim Biophys
Acta. 1773:1238–1247. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
O'Neill E, Rushworth L, Baccarini M and
Kolch W: Role of the kinase MST2 in suppression of apoptosis by the
proto-oncogene product Raf-1. Science. 306:2267–2270. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Romano D, Matallanas D, Weitsman G,
Preisinger C, Ng T and Kolch W: Proapoptotic kinase MST2
coordinates signaling crosstalk between RASSF1A, Raf-1, and Akt.
Cancer Res. 70:1195–1203. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hay BA and Guo M: Coupling cell growth,
proliferation, and death. Hippo weighs in. Dev Cell. 5:361–363.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Avruch J, Zhou D, Fitamant J, Bardeesy N,
Mou F and Barrufet LR: Protein kinases of the Hippo pathway:
Regulation and substrates. Semin Cell Dev Biol. 23:770–784. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Romano D, Nguyen LK, Matallanas D, Halasz
M, Doherty C, Kholodenko BN and Kolch W: Protein interaction
switches coordinate Raf-1 and MST2/Hippo signalling. Nat Cell Biol.
16:673–684. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lamar JM, Stern P, Liu H, Schindler JW,
Jiang ZG and Hynes RO: The Hippo pathway target, YAP, promotes
metastasis through its TEAD-interaction domain. Proc Natl Acad Sci
USA. 109:E2441–E2450. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yu FX, Meng Z, Plouffe SW and Guan KL:
Hippo pathway regulation of gastrointestinal tissues. Annu Rev
Physiol. 77:201–227. 2015. View Article : Google Scholar : PubMed/NCBI
|
